Actively Recruiting
Phase 2 Study of EMLA Cream to Reduce Pain from Technetium 99 Injections During Lymphoscintigraphy for Skin Cancer Patients
Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-03-10
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether EMLA topical cream, which contains numbing medicines lidocaine and prilocaine, can reduce pain in patients with skin cancers undergoing Technetium 99 injections for a lymphoscintigraphy mapping procedure. This procedure helps locate key lymph nodes for removal and tumor checking, which is a common treatment for skin cancer. The study focuses on pain caused by the injections and aims to see if EMLA cream can improve comfort during the procedure. In this phase II trial, patients are randomly assigned to one of two groups. One group applies EMLA cream to the skin 30 minutes before receiving the Technetium 99 injection, while the other group applies a placebo cream at the same time. Both treatments are applied topically to the skin before the lymphoscintigraphy procedure. Participants will be evaluated for pain scores up to one year after the procedure and monitored for any adverse events within 30 minutes after injection. The study includes questionnaires and other assessments to gather information about pain and safety. Total participation duration varies, with follow-up assessments to measure outcomes and monitor patient well-being over time.
CONDITIONS
Brief Title
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Research Team
T
The Ohio State University Comprehensive Cancer Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here